DGX

Quest Diagnostics
D

DGX

Arincen63/100B

Quest Diagnostics executives and insider trading

James E. Davis reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Quest Diagnostics's insiders sold 201,427 shares for 42.69M USD in 36 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
36
Shares sold
201,427
Value sold
42.69M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
5.48M USD
0
1 month
5.77M USD
0
3 months
13.72M USD
0
6 months
17.66M USD
0
1 year
42.69M USD
0
2 years
73.42M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
J. E. Davis Director, CEO and President—85,09317.08M USD—1 Sept 2026122,423
Catherine T. Doherty Executive Vice President of Regional Businesses6355,89312.45M USD—3 Nov 202694,054
Michael E. Prevoznik Senior Vice President & General Counsel6428,1926.65M USD—28 Aug 202660,234
Karthik Kuppusamy Senior Vice President of Clinical Solutions5610,7752.17M USD—4 Jun 202613,619
Patrick Plewman SVP for Diagnostic Services—9,4751.94M USD—5 Mar 202615,334
Mark E Delaney SVP & Chief Commercial Officer—9,5461.86M USD—28 Jul 202612,975
Gary M Pfeiffer Director—1,203292.33K USD—26 Oct 202629,802
Vicky B Gregg Director—1,250239.70K USD—25 Nov 202518,449

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
3 Nov 2026Catherine T. DohertySale3,818245.45937.14K USD90,236Form 4
3 Nov 2026Catherine T. DohertySale5,990246.261.48M USD84,246Form 4
3 Nov 2026Catherine T. DohertySale1,151246.98284.28K USD83,095Form 4
3 Nov 2026Catherine T. DohertySale2,358248.38585.69K USD80,737Form 4
3 Nov 2026Catherine T. DohertySale3,004249.40749.21K USD77,733Form 4
3 Nov 2026Catherine T. DohertySale2,877250.49720.65K USD74,856Form 4
3 Nov 2026Catherine T. DohertySale2,907251.24730.35K USD71,949Form 4
26 Oct 2026Gary M PfeifferSale1,203243.00292.33K USD29,802Form 4
1 Sept 2026J. E. DavisSale10,000242.722.43M USD122,423Form 4
28 Aug 2026Michael E. PrevoznikSale16,010242.883.89M USD44,224Form 4
28 Aug 2026Michael E. PrevoznikSale6,237243.631.52M USD37,987Form 4
28 Aug 2026Michael E. PrevoznikSale430244.51105.14K USD37,557Form 4
28 Jul 2026Mark E DelaneySale1,600235.18376.29K USD10,335Form 4
4 Jun 2026Karthik KuppusamySale8,147200.001.63M USD13,510Form 4
1 Jun 2026J. E. DavisSale10,000194.141.94M USD132,423Form 4

Common questions about Quest Diagnostics's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.